NCT04168385 - MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

September 4, 2024

Study Completion Date

September 4, 2024

Conditions

Cholestatic Liver Disease

Interventions

DRUG

Maralixibat

"Maralixibat chloride oral solution orally twice daily (up to 1200\* mcg/kg/day), and according to indication.~\*equivalent to 1140 mcg/kg/day maralixibat"

Trial Locations (17)

261

Hospital Universitario La Paz- Hospital Materno Infantil, Madrid

2145

Children's Hospital Westmead, Westmead

3052

The Royal Children'S Hospital Melbourne, Parkville

15224

Children Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

46202

Riley Hospital For Children, Indianapolis

75015

Hopital Necker-Enfants Malades, Paris

77030

Baylor College of Medicine/Texas Children's Hospital, Houston

90027

Children'S Hospital Los Angeles, Los Angeles

94275

Hopital Kremlin Bicetre, Paris

98105

Seattle Children's Hospital, Seattle

Unknown

Cliniques Universitaires Saint-Luc, Brussels

Hospital for Sick Children, Toronto

Birmingham Children's Hospital, Birmingham

04-730

The Children's Memorial Health Institute, Warsaw

LS1 3EX

Leeds Teaching Hospital NHS Trust, Leeds

SE5 9RS

Paediatric Liver Center, Kings College Hospital, London